Kyverna Therapeutics, Inc.
KYTXNASDAQHealthcare● Active
$7.47
$-0.48(-6.04%)
Market Cap$327124066
P/E Ratio—
52W High$13.67
52W Low$2.52
Kyverna Therapeutics, Inc. (KYTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KYTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.01B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | ($0.00B) | ($0.00B) | $0.01B | $0.01B |
| Gross Margin %(computed) | — | — | — | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.13B | $0.11B | $0.05B | $0.03B | $0.03B |
| G&A Expenses | $0.04B | $0.03B | $0.00B | $0.01B | $0.01B |
| Total Operating Expenses | $0.17B | $0.14B | $0.06B | $0.04B | $0.03B |
| Operating Income | ($0.17B) | ($0.14B) | ($0.06B) | ($0.03B) | ($0.03B) |
| Operating Margin %(computed) | — | — | — | -418.28% | -465.81% |
| Interest Income | $0.01B | $0.02B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.16B) | ($0.13B) | ($0.06B) | ($0.03B) | ($0.03B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.16B) | ($0.13B) | ($0.06B) | ($0.03B) | ($0.03B) |
| Net Margin %(computed) | — | — | — | -411.29% | -465.88% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.64 | $-3.33 | $-0.00 | $-1.12 | $-1.02 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.67B | 0.03B | 0.03B |
| EBITDA | ($0.16B) | ($0.13B) | ($0.06B) | ($0.03B) | ($0.03B) |
| EBITDA Margin %(computed) | — | — | — | -395.40% | -455.46% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Kyverna Therapeutics, Inc. data
About Kyverna Therapeutics, Inc. (KYTX) Income Statement
Kyverna Therapeutics, Inc. (KYTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KYTX reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.16B) — a net profit margin of —.
Frequently asked questions
KYTX · 4 questionsKyverna Therapeutics, Inc. (KYTX) reported revenue of $0.00B for 2025, down —% year-over-year.
KYTX revenueKYTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08